quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:23·8d
INSIDERFiling
Celularity Inc. logo

SEC Form 4 filed by Haines John R

CELU· Celularity Inc.
Health Care
Original source

Companies

  • CELU
    Celularity Inc.
    Health Care

Recent analyst ratings

  • Jan 30UpdateMorgan Stanley$1.00
  • Dec 22UpdateOppenheimer-
  • Jun 22UpdateH.C. Wainwright$15.00
  • Apr 6UpdateTruist$10.00
  • Jan 28UpdateOppenheimer$9.00
  • Nov 24UpdateMorgan Stanley$9.00

Related

  • SEC1d
    Amendment: SEC Form SCHEDULE 13D/A filed by Celularity Inc.
  • SEC2d
    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Leadership Update, Other Events, Financial Statements and Exhibits
  • PR2d
    NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
  • PR2d
    Celularity Announces Closing of Transaction with NexGel
  • PR6d
    Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
  • INSIDER8d
    SEC Form 4 filed by Hariri Robert J
  • INSIDER8d
    SEC Form 4 filed by Brigido Stephen
  • SEC23d
    SEC Form NT 10-K filed by Celularity Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022